What changed from existing technology?
The study found that some patients with a certain genetic marker had a higher risk of liver damage when taking a new drug for a brain disease.
This is the first study to link a specific HLA allele with drug-induced liver injury in patients treated with KM-819 for multiple system atrophy.
Commercialization signals visible at publication
This is not a success probability or investment opinion. It prioritizes follow-up using evidence available when the paper was published.
Verified evidence · 1
f drug-induced liver injury in multiple system atrophy patients treated with KM-819 is potentially associated with the HLA-DPB1*05:01:01:01 allele. KM-819, a
Title ↗- 시제품·장치 구현 근거 미확인
- 제조·규모 확장 근거 미확인
Later patent, company, clinical, and production events are added separately only after verification.
Patent check: Not checked yetCurrent technology stage: Near commercialization
See what changed before reading the full paper.
What still needs to be solved?
Repeated real-world validation, manufacturability, cost, and long-term stability still require follow-up evidence.
What could change if this succeeds?
This finding suggests that genetic screening for HLA-DPB1*05:01:01:01 may help identify MSA patients at higher risk of liver injury from KM-819 treatment.
Keep following this technology
Revisit changes when new papers, patents, company participation, validation, or products appear.